Compare IRMD & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRMD | ARDX |
|---|---|---|
| Founded | 1992 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 996.8M |
| IPO Year | 2014 | 2014 |
| Metric | IRMD | ARDX |
|---|---|---|
| Price | $87.61 | $3.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $116.00 | $15.14 |
| AVG Volume (30 Days) | 108.2K | ★ 4.8M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $83,814,000.00 | $2,607,000.00 |
| Revenue This Year | $12.38 | $37.75 |
| Revenue Next Year | $11.31 | $34.24 |
| P/E Ratio | $101.16 | ★ N/A |
| Revenue Growth | ★ 14.43 | N/A |
| 52 Week Low | $67.84 | $3.73 |
| 52 Week High | $107.90 | $8.40 |
| Indicator | IRMD | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 27.50 |
| Support Level | $84.05 | N/A |
| Resistance Level | $88.72 | $6.47 |
| Average True Range (ATR) | 2.33 | 0.14 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 32.47 | 12.33 |
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.